Copyright
©The Author(s) 2024.
World J Hepatol. Feb 27, 2024; 16(2): 211-228
Published online Feb 27, 2024. doi: 10.4254/wjh.v16.i2.211
Published online Feb 27, 2024. doi: 10.4254/wjh.v16.i2.211
Figure 4 Proportion of hepatocellular carcinoma treatment modality in different groups, expressed by crude incidence rate (events/10000 person-years).
HCC: Hepatocellular carcinoma; COVID-19: Coronavirus disease 2019.
- Citation: Mak LY, Chung MSH, Li X, Lai FTT, Wan EYF, Chui CSL, Cheng FWT, Chan EWY, Cheung CL, Au ICH, Xiong X, Seto WK, Yuen MF, Wong CKH, Wong ICK. Effects of SARS-CoV-2 infection on incidence and treatment strategies of hepatocellular carcinoma in people with chronic liver disease. World J Hepatol 2024; 16(2): 211-228
- URL: https://www.wjgnet.com/1948-5182/full/v16/i2/211.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i2.211